Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for lamivudine / tenofovir disoproxil, the scientific conclusions are as follows:

In view of available cumulative data on bone density decreased from clinical trials, post-marketing experience, cases from literature including in some cases a close temporal relationship, and epidemiological studies, the PRAC considers a causal relationship between lamivudine / tenofovir disoproxil and bone density decreased is at least a reasonable possibility. The PRAC concluded that the product information of products containing lamivudine / tenofovir disoproxil should be amended accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for lamivudine / tenofovir disoproxil the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing lamivudine / tenofovir disoproxil is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing lamivudine / tenofovir disoproxil are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

Section 4.8

The following adverse reaction should be added under the SOC Musculoskeletal and connective tissue disorders with a frequency not known:

Tenofovir disoproxil

Bone density decreased[3]

[3] See section 4.4

Package Leaflet

Section 4

Other side effects:

Tenofovir disoproxil

Not known (cannot be estimated from the available data)

Loss of bone mass

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	December 2022 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	17 February 2023
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	19 May 2023